Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Propylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylamine SCHEMBL17077494 | 1.00 | DNM1 (0.47) | — | |
| Propylamine SCHEMBL28010272 | 1.00 | DNM1 (0.47) | — | |
| Propylamine SCHEMBL27499864 | 1.00 | — | — | |
| Propylamine SCHEMBL28010271 | 1.00 | — | — | |
| Propylamine SCHEMBL1193755 | 1.00 | — | — | |
| Propylamine SCHEMBL27329106 | 0.95 | — | — | |
| Propylamine SCHEMBL8379229 | 0.95 | — | — | |
| Propylamine SCHEMBL27989799 | 0.95 | — | — | |
| Propylamine SCHEMBL1330797 | 0.94 | — | — | |
| Propylamine SCHEMBL448871 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | THERAGENICS CORPORATION | 2019-08-29 | — | — | US | claimed |
| CN-106190450-B | A kind of alcohol ether borate type braking fluid | 辽宁道博精细化学品生产有限公司 | 2019-07-16 | — | — | CN | claimed |
| CN-106190450-A | A kind of alcohol ether borate type braking fluid | 辽宁道博精细化学品生产有限公司 | 2016-12-07 | — | — | CN | claimed |
| CN-106190451-A | A kind of preparation method of alcohol ether borate type braking fluid | 辽宁道博精细化学品生产有限公司 | 2016-12-07 | — | — | CN | claimed |
| EP-2846847-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | Medicus Biosciences LLC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | claimed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2023-07-13 | — | — | US | disclosed |
| EP-2968680-B1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | C P MEDICAL CORP (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | AQUARIAN CREDIT FUNDING LLC | 2023-03-07 | — | — | US | disclosed |
| US-20210322785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | THERAGENICS CORPORATION | 2021-10-21 | — | — | US | disclosed |
| EP-3893785-A1 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | C.P. Medical Corporation (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11083821-B2 | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules | C.P. MEDICAL CORPORATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130108711-A1 | METHODS FOR TREATING DISEASES OF THE LUNG | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2011140517-A2 | METHODS FOR TREATING DISEASES OF THE LUNG | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| CN-101500409-A | Improved tissue maintenance | HIBERNATION THERAPEUTICS LTD (AU) | 2009-08-05 | — | — | CN | disclosed |
| US-4707454-A | Fluorescent chlorophyll labeled assay reagents | BIO-DIAGNOSTICS, INC. (US) | 1987-11-17 | — | — | US | disclosed |